Whalesbook
Zydus Lifesciences' stock price climbed to a 52-week high after the company announced strong fourth-quarter fiscal year 2026 results. Net profit rose 8.7% year-on-year to ₹1,272.5 crore, on revenues that grew 16.2% to ₹7,587 crore. This performance surpassed analyst expectations. The board also approved a ₹1,100 crore share buyback program at ₹1,150 per share, indicating management's confidence in the company's valuation and future. The stock reached ₹1,091 amid a declining broader market, with the BSE Sensex seeing a dip.
Valuation and Growth Outlook
Zydus Lifesciences trades at a Price-to-Earnings (P/E) ratio of 18.6x to 20.4x (TTM), which appears attractive compared to the industry average P/E of approximately 34.74. The company's market capitalization is around ₹1,02,530 crore. For the full year FY25, revenue grew 18.9% year-on-year to ₹23,241 crore, and net profit rose 20.4% to ₹4,614 crore. Zydus Lifesciences projects high-teen growth for FY27. The company is outperforming the Indian market by an expected 200-400 basis points and saw international market growth of 45% year-on-year in Q4. New biosimilars, Tishtha and Anyra, have been launched.
Potential Challenges
Despite the strong results, margin volatility has been observed. JM Financial noted concerns about revenue and EBITDA growth for the next two years, forecasting potential erosion in key U.S. products due to competition. Products like GRevlimed and Mirabegron in the U.S. market may be affected. The North American formulations business saw a 6% year-on-year decline in Q4. Investors will be watching how Zydus Lifesciences handles pricing pressures and competition in the U.S.